| Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2020: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2018: ¥9,230,000 (Direct Cost: ¥7,100,000、Indirect Cost: ¥2,130,000)
|
|---|
| Outline of Final Research Achievements |
Mitochondrial disease is one kind of intractable disease for which the diagnosis is still complicated by the distinct lack of sensitive and specific biomarkers and remedies.We reported that a new indole-derivative drug, MA-5, improved the cardiac and renal respiration and prolonged survival in diseas model mice carrying a deleted mitochondrial DNA mutation that makes it suitable for evaluating the phenotype of human mitochondrial diseases and renal diseases. In addition, mitochondrial disease is one kind of intractable disease for which the diagnosis is still complicated by the distinct lack of sensitive and specific biomarkers.
We found the potential biomarkers for mitochondrial dysfunction to improve diagnoses and develop new medicines to ameliorate the mitochondrial diseases.
|
